Nuvalent, INC 10-Q quarterly reports

Nuvalent, Inc. reported its first-quarter 2026 financial results, highlighting continued progress in its clinical-stage biopharmaceutical pipeline with key regulatory milestones and trial updates.

Nuvalent, Inc. reports significant clinical progress for its oncology pipeline, including a completed NDA submission for zidesamtinib, amidst increasing net losses and a projected need for additional capital by 2028.

Nuvalent, Inc. announced positive pivotal data for zidesamtinib in ROS1-positive NSCLC and initiated a Phase 3 trial for neladalkib, while reporting increased net losses.

Nuvalent, Inc. announces its Q1 2025 financial results and provides updates on its clinical-stage programs, including zidesamtinib, neladalkib, and NVL-330.

Nuvalent, a clinical-stage biopharmaceutical company, released its Q3 2024 financial results and provided updates on its ongoing clinical trials for cancer therapies.

Nuvalent, a clinical-stage biopharmaceutical company, released its second quarter 2024 financial results, highlighting ongoing clinical trials and research and development activities.

Nuvalent, a clinical-stage biopharmaceutical company, reported a net loss of $44.5 million for the first quarter of 2024, while advancing its clinical programs for targeted cancer therapies.